Publications
-
CD271(+) bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis.
Das B,
Kashino SS, Pulu I, Kalita D, Swami V, Yeger H, Felsher DW, Campos-Neto A.
Sci Transl Med.
2013;
5
(170):
170ra13
-
"Picolog," a synthetically-available bryostatin analog, inhibits growth of MYC-induced lymphoma in vivo.
DeChristopher BA,
Fan AC, Felsher DW, Wender PA.
Oncotarget.
2012;
3
(1):
58-66
-
Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction.
Bachireddy P,
Rakhra K, Felsher DW.
Clin Exp Immunol.
2012;
167
(2):
188-94
-
Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis.
Tran PT,
Shroff EH, Burns TF, Thiyagarajan S, Das ST, Zabuawala T, Chen J, Cho YJ, Luong R, Tamayo P, Salih T, Aziz K, Adam SJ, Vicent S, Nielsen CH, Withofs N, Sweet-Cordero A, Gambhir SS, Rudin CM, Felsher DW.
PLoS Genet.
2012;
8
(5):
e1002650
-
Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction.
Choi PS,
van Riggelen J, Gentles AJ, Bachireddy P, Rakhra K, Adam SJ, Plevritis SK, Felsher DW.
Proc Natl Acad Sci U S A.
2011;
108
(42):
17432-7
-
Survival and death signals can predict tumor response to therapy after oncogene inactivation.
Tran PT,
Bendapudi PK, Lin HJ, Choi P, Koh S, Chen J, Horng G, Hughes NP, Schwartz LH, Miller VA, Kawashima T, Kitamura T, Paik D, Felsher DW.
Sci Transl Med.
2011;
3
(103):
103ra99
-
CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation.
Rakhra K,
Bachireddy P, Zabuawala T, Zeiser R, Xu L, Kopelman A, Fan AC, Yang Q, Braunstein L, Crosby E, Ryeom S, Felsher DW.
Cancer Cell.
2010;
18
(5):
485-98
-
MYC as a regulator of ribosome biogenesis and protein synthesis.
van Riggelen J,
Yetil A, Felsher DW.
Nat Rev Cancer.
2010;
10
(4):
301-9
-
The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance.
van Riggelen J,
Müller J, Otto T, Beuger V, Yetil A, Choi PS, Kosan C, Möröy T, Felsher DW, Eilers M.
Genes Dev.
2010;
24
(12):
1281-94
-
Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens.
Fan AC,
Deb-Basu D, Orban MW, Gotlib JR, Natkunam Y, O'Neill R, Padua RA, Xu L, Taketa D, Shirer AE, Beer S, Yee AX, Voehringer DW, Felsher DW.
Nat Med.
2009;
15
(5):
566-71
-
Combined analysis of murine and human microarrays and ChIP analysis reveals genes associated with the ability of MYC to maintain tumorigenesis.
Wu CH,
Sahoo D, Arvanitis C, Bradon N, Dill DL, Felsher DW.
PLoS Genet.
2008;
4
(6):
e1000090
-
Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation.
Wu CH,
van Riggelen J, Yetil A, Fan AC, Bachireddy P, Felsher DW.
Proc Natl Acad Sci U S A.
2007;
104
(32):
13028-33
-
Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch.
Giuriato S,
Ryeom S, Fan AC, Bachireddy P, Lynch RC, Rioth MJ, van Riggelen J, Kopelman AM, Passegué E, Tang F, Folkman J, Felsher DW.
Proc Natl Acad Sci U S A.
2006;
103
(44):
16266-71
-
Developmental context determines latency of MYC-induced tumorigenesis.
Beer S,
Zetterberg A, Ihrie RA, McTaggart RA, Yang Q, Bradon N, Arvanitis C, Attardi LD, Feng S, Ruebner B, Cardiff RD, Felsher DW.
PLoS Biol.
2004;
2
(11):
e332
-
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer.
Shachaf CM,
Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, Yang Q, Bishop JM, Contag CH, Felsher DW.
Nature.
2004;
431
(7012):
1112-7
-
Cancer revoked: oncogenes as therapeutic targets.
Felsher DW,
Nat Rev Cancer.
2003;
3
(5):
375-80
-
Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression.
Karlsson A,
Deb-Basu D, Cherry A, Turner S, Ford J, Felsher DW.
Proc Natl Acad Sci U S A.
2003;
100
(17):
9974-9
-
Sustained loss of a neoplastic phenotype by brief inactivation of MYC.
Jain M,
Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, Sundberg CD, Bishop JM, Felsher DW.
Science.
2002;
297
(5578):
102-4
-
Characterization of MYC-Induced Tumorigenesis by in Situ Lipid Profiling.
Perry RH,
Bellovin DI, Shroff EH, Ismail AI, Zabuawala T, Felsher DW, Zare RN.
Anal Chem.
2013
-
In vivo imaging-based mathematical modeling techniques that enhance the understanding of oncogene addiction in relation to tumor growth.
Nwabugwu C,
Rakhra K, Felsher D, Paik D.
Comput Math Methods Med.
2013:
2013
802512
-
Noncanonical roles of the immune system in eliciting oncogene addiction.
Casey SC,
Bellovin DI, Felsher DW.
Curr Opin Immunol.
2013;
25
(2):
246-58
-
Role of MYCN in retinoblastoma.
Felsher DW,
Lancet Oncol.
2013;
14
(4):
270-1
-
Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs.
Bellovin DI,
Das B, Felsher DW.
Adv Exp Med Biol.
2013:
734
91-107
-
Cryptococcal osteomyelitis and meningitis in a patient with non-hodgkin's lymphoma treated with PEP-C.
To CA,
Hsieh RW, McClellan JS, Howard W, Fischbein NJ, Brown JM, Felsher DW, Fan AC.
BMJ Case Rep.
2012
2012
-
HIF-2α suppresses p53 to enhance the stemness and regenerative potential of human embryonic stem cells.
Das B,
Bayat-Mokhtari R, Tsui M, Lotfi S, Tsuchida R, Felsher DW, Yeger H.
Stem Cells.
2012;
30
(8):
1685-95
-
High throughput automated chromatin immunoprecipitation as a platform for drug screening and antibody validation.
Wu AR,
Kawahara TL, Rapicavoli NA, van Riggelen J, Shroff EH, Xu L, Felsher DW, Chang HY, Quake SR.
Lab Chip.
2012;
12
(12):
2190-8
-
Loss of Dnmt3b function upregulates the tumor modifier Ment and accelerates mouse lymphomagenesis.
Hlady RA,
Novakova S, Opavska J, Klinkebiel D, Peters SL, Bies J, Hannah J, Iqbal J, Anderson KM, Siebler HM, Smith LM, Greiner TC, Bastola D, Joshi S, Lockridge O, Simpson MA, Felsher DW, Wagner KU, Chan WC, Christman JK, Opavsky R.
J Clin Invest.
2012;
122
(1):
163-77
-
SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas.
Jang KY,
Noh SJ, Lehwald N, Tao GZ, Bellovin DI, Park HS, Moon WS, Felsher DW, Sylvester KG.
PLoS One.
2012;
7
(9):
e45119
-
STK38 is a critical upstream regulator of MYC's oncogenic activity in human B-cell lymphoma.
Bisikirska BC,
Adam SJ, Alvarez MJ, Rajbhandari P, Cox R, Lefebvre C, Wang K, Rieckhof GE, Felsher DW, Califano A.
Oncogene.
2012
-
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Seetharam M,
Fan AC, Tran M, Xu L, Renschler JP, Felsher DW, Sridhar K, Wilhelm F, Greenberg PL.
Leuk Res.
2012;
36
(1):
98-103
-
Functional interactions between retinoblastoma and c-MYC in a mouse model of hepatocellular carcinoma.
Saddic LA,
Wirt S, Vogel H, Felsher DW, Sage J.
PLoS One.
2011;
6
(5):
e19758
-
Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas.
Dejean E,
Renalier MH, Foisseau M, Agirre X, Joseph N, de Paiva GR, Al Saati T, Soulier J, Desjobert C, Lamant L, Prósper F, Felsher DW, Cavaillé J, Prats H, Delsol G, Giuriato S, Meggetto F.
Leukemia.
2011;
25
(12):
1882-90
-
MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase.
Cao Z,
Fan-Minogue H, Bellovin DI, Yevtodiyenko A, Arzeno J, Yang Q, Gambhir SS, Felsher DW.
Cancer Res.
2011;
71
(6):
2286-97
-
Reactive oxygen species regulate nucleostemin oligomerization and protein degradation.
Huang M,
Whang P, Chodaparambil JV, Pollyea DA, Kusler B, Xu L, Felsher DW, Mitchell BS.
J Biol Chem.
2011;
286
(13):
11035-46
-
Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia.
Giuriato S,
Foisseau M, Dejean E, Felsher DW, Al Saati T, Demur C, Ragab A, Kruczynski A, Schiff C, Delsol G, Meggetto F.
Blood.
2010;
115
(20):
4061-70
-
Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cells.
Contag CH,
Sikorski R, Negrin RS, Schmidt T, Fan AC, Bachireddy P, Felsher DW, Thorne SH.
Cancer Res.
2010;
70
(23):
9837-45
-
Development of a micro-computed tomography-based image-guided conformal radiotherapy system for small animals.
Zhou H,
Rodriguez M, van den Haak F, Nelson G, Jogani R, Xu J, Zhu X, Xian Y, Tran PT, Felsher DW, Keall PJ, Graves EE.
Int J Radiat Oncol Biol Phys.
2010;
78
(1):
297-305
-
Hypoxia in models of lung cancer: implications for targeted therapeutics.
Graves EE,
Vilalta M, Cecic IK, Erler JT, Tran PT, Felsher D, Sayles L, Sweet-Cordero A, Le QT, Giaccia AJ.
Clin Cancer Res.
2010;
16
(19):
4843-52
-
Impact of hydrodynamic injection and phiC31 integrase on tumor latency in a mouse model of MYC-induced hepatocellular carcinoma.
Woodard LE,
Keravala A, Jung WE, Wapinski OL, Yang Q, Felsher DW, Calos MP.
PLoS One.
2010;
5
(6):
e11367
-
Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice.
Beer S,
Bellovin DI, Lee JS, Komatsubara K, Wang LS, Koh H, Börner K, Storm TA, Davis CR, Kay MA, Felsher DW, Grimm D.
Mol Ther.
2010;
18
(1):
161-70
-
MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms.
Felsher DW,
Genes Cancer.
2010;
1
(6):
597-604
-
Myc and a Cdk2 senescence switch.
van Riggelen J,
Felsher DW.
Nat Cell Biol.
2010;
12
(1):
7-9
-
Noninvasive molecular imaging of c-Myc activation in living mice.
Fan-Minogue H,
Cao Z, Paulmurugan R, Chan CT, Massoud TF, Felsher DW, Gambhir SS.
Proc Natl Acad Sci U S A.
2010;
107
(36):
15892-7
-
PET imaging of tumor neovascularization in a transgenic mouse model with a novel 64Cu-DOTA-knottin peptide.
Nielsen CH,
Kimura RH, Withofs N, Tran PT, Miao Z, Cochran JR, Cheng Z, Felsher D, Kjær A, Willmann JK, Gambhir SS.
Cancer Res.
2010;
70
(22):
9022-30
-
TGFβ-dependent gene expression shows that senescence correlates with abortive differentiation along several lineages in Myc-induced lymphomas.
Müller J,
Samans B, van Riggelen J, Fagà G, Peh K N R, Wei CL, Müller H, Amati B, Felsher D, Eilers M.
Cell Cycle.
2010;
9
(23):
4622-6
-
Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage-response thresholds.
Kampa KM,
Acoba JD, Chen D, Gay J, Lee H, Beemer K, Padiernos E, Boonmark N, Zhu Z, Fan AC, Bailey AS, Fleming WH, Corless C, Felsher DW, Naumovski L, Lopez CD.
Proc Natl Acad Sci U S A.
2009;
106
(11):
4390-5
-
Autochthonous liver tumors induce systemic T cell tolerance associated with T cell receptor down-modulation.
Ney JT,
Schmidt T, Kurts C, Zhou Q, Eckert D, Felsher DW, Schorle H, Knolle P, Tüting T, Barchet W, Büttner R, Limmer A, Gütgemann I.
Hepatology.
2009;
49
(2):
471-81
-
Cell cycle re-entry and mitochondrial defects in myc-mediated hypertrophic cardiomyopathy and heart failure.
Lee HG,
Chen Q, Wolfram JA, Richardson SL, Liner A, Siedlak SL, Zhu X, Ziats NP, Fujioka H, Felsher DW, Castellani RJ, Valencik ML, McDonald JA, Hoit BD, Lesnefsky EJ, Smith MA.
PLoS One.
2009;
4
(9):
e7172
-
SPECT and PET imaging of EGF receptors with site-specifically labeled EGF and dimeric EGF.
Levashova Z,
Backer MV, Horng G, Felsher D, Backer JM, Blankenberg FG.
Bioconjug Chem.
2009;
20
(4):
742-9
-
Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy.
Liu Z,
Fan AC, Rakhra K, Sherlock S, Goodwin A, Chen X, Yang Q, Felsher DW, Dai H.
Angew Chem Int Ed Engl.
2009;
48
(41):
7668-72
-
The neuronal expression of MYC causes a neurodegenerative phenotype in a novel transgenic mouse.
Lee HG,
Casadesus G, Nunomura A, Zhu X, Castellani RJ, Richardson SL, Perry G, Felsher DW, Petersen RB, Smith MA.
Am J Pathol.
2009;
174
(3):
891-7
-
Tumor dormancy and oncogene addiction.
Felsher DW,
APMIS.
2008 Jul-Aug;
116
(7-8):
629-37
-
(18)F and (18)FDG PET imaging of osteosarcoma to non-invasively monitor in situ changes in cellular proliferation and bone differentiation upon MYC inactivation.
Arvanitis C,
Bendapudi PK, Tseng JR, Gambhir SS, Felsher DW.
Cancer Biol Ther.
2008;
7
(12):
1947-51
-
A quantitative PCR method to detect blood microRNAs associated with tumorigenesis in transgenic mice.
Fan AC,
Goldrick MM, Ho J, Liang Y, Bachireddy P, Felsher DW.
Mol Cancer.
2008:
7
74
-
An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice.
Traykova-Brauch M,
Schönig K, Greiner O, Miloud T, Jauch A, Bode M, Felsher DW, Glick AB, Kwiatkowski DJ, Bujard H, Horst J, von Knebel Doeberitz M, Niggli FK, Kriz W, Gröne HJ, Koesters R.
Nat Med.
2008;
14
(9):
979-84
-
Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas.
Tran PT,
Fan AC, Bendapudi PK, Koh S, Komatsubara K, Chen J, Horng G, Bellovin DI, Giuriato S, Wang CS, Whitsett JA, Felsher DW.
PLoS One.
2008;
3
(5):
e2125
-
Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance.
Shachaf CM,
Gentles AJ, Elchuri S, Sahoo D, Soen Y, Sharpe O, Perez OD, Chang M, Mitchel D, Robinson WH, Dill D, Nolan GP, Plevritis SK, Felsher DW.
Cancer Res.
2008;
68
(13):
5132-42
-
Hepatotoxin-induced changes in the adult murine liver promote MYC-induced tumorigenesis.
Beer S,
Komatsubara K, Bellovin DI, Kurobe M, Sylvester K, Felsher DW.
PLoS One.
2008;
3
(6):
e2493
-
Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit?
Felsher DW,
Cancer Res.
2008;
68
(9):
3081-6; discussion 3086
-
Reversing cancer from inside and out: oncogene addiction, cellular senescence, and the angiogenic switch.
Felsher DW,
Lymphat Res Biol.
2008;
6
(3-4):
149-54
-
The current STATe of biomarkers to predict the response to anti-angiogenic therapies.
Tran PT,
Felsher DW.
Cancer Biol Ther.
2008;
7
(12):
2004-6
-
BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia.
Omidvar N,
Kogan S, Beurlet S, le Pogam C, Janin A, West R, Noguera ME, Reboul M, Soulie A, Leboeuf C, Setterblad N, Felsher D, Lagasse E, Mohamedali A, Thomas NS, Fenaux P, Fontenay M, Pla M, Mufti GJ, Weissman I, Chomienne C, Padua RA.
Cancer Res.
2007;
67
(24):
11657-67
-
CpG island methylation in a mouse model of lymphoma is driven by the genetic configuration of tumor cells.
Opavsky R,
Wang SH, Trikha P, Raval A, Huang Y, Wu YZ, Rodriguez B, Keller B, Liyanarachchi S, Wei G, Davuluri RV, Weinstein M, Felsher D, Ostrowski M, Leone G, Plass C.
PLoS Genet.
2007;
3
(9):
1757-69
-
Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy.
Giuriato S,
Faumont N, Bousquet E, Foisseau M, Bibonne A, Moreau M, Al Saati T, Felsher DW, Delsol G, Meggetto F.
Cancer Biol Ther.
2007;
6
(8):
1318-23
-
Enhanced NFATc1 nuclear occupancy causes T cell activation independent of CD28 costimulation.
Pan M,
Winslow MM, Chen L, Kuo A, Felsher D, Crabtree GR.
J Immunol.
2007;
178
(7):
4315-21
-
HIF-dependent antitumorigenic effect of antioxidants in vivo.
Gao P,
Zhang H, Dinavahi R, Li F, Xiang Y, Raman V, Bhujwalla ZM, Felsher DW, Cheng L, Pevsner J, Lee LA, Semenza GL, Dang CV.
Cancer Cell.
2007;
12
(3):
230-8
-
Identifying critical signaling molecules for the treatment of cancer.
Arvanitis C,
Bendapudi PK, Bachireddy P, Felsher DW.
Recent Results Cancer Res.
2007:
172
5-24
-
Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis.
Shachaf CM,
Perez OD, Youssef S, Fan AC, Elchuri S, Goldstein MJ, Shirer AE, Sharpe O, Chen J, Mitchell DJ, Chang M, Nolan GP, Steinman L, Felsher DW.
Blood.
2007;
110
(7):
2674-84
-
Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis.
Opavsky R,
Tsai SY, Guimond M, Arora A, Opavska J, Becknell B, Kaufmann M, Walton NA, Stephens JA, Fernandez SA, Muthusamy N, Felsher DW, Porcu P, Caligiuri MA, Leone G.
Proc Natl Acad Sci U S A.
2007;
104
(39):
15400-5
-
CDK2 is required by MYC to induce apoptosis.
Deb-Basu D,
Aleem E, Kaldis P, Felsher DW.
Cell Cycle.
2006;
5
(12):
1342-7
-
Conditional transgenic models define how MYC initiates and maintains tumorigenesis.
Arvanitis C,
Felsher DW.
Semin Cancer Biol.
2006;
16
(4):
313-7
-
MYC can enforce cell cycle transit from G1 to S and G2 to S, but not mitotic cellular division, independent of p27-mediated inihibition of cyclin E/CDK2.
Deb-Basu D,
Karlsson A, Li Q, Dang CV, Felsher DW.
Cell Cycle.
2006;
5
(12):
1348-55
-
MYC can induce DNA breaks in vivo and in vitro independent of reactive oxygen species.
Ray S,
Atkuri KR, Deb-Basu D, Adler AS, Chang HY, Herzenberg LA, Felsher DW.
Cancer Res.
2006;
66
(13):
6598-605
-
Tumor dormancy: death and resurrection of cancer as seen through transgenic mouse models.
Felsher DW,
Cell Cycle.
2006;
5
(16):
1808-11
-
c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma.
Weng AP,
Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, Wai C, Del Bianco C, Rodriguez CG, Sai H, Tobias J, Li Y, Wolfe MS, Shachaf C, Felsher D, Blacklow SC, Pear WS, Aster JC.
Genes Dev.
2006;
20
(15):
2096-109
-
Comparative genomic hybridization on mouse cDNA microarrays and its application to a murine lymphoma model.
Sander S,
Bullinger L, Karlsson A, Giuriato S, Hernandez-Boussard T, Felsher DW, Pollack JR.
Oncogene.
2005;
24
(40):
6101-7
-
Conditionally MYC: insights from novel transgenic models.
Arvanitis C,
Felsher DW.
Cancer Lett.
2005;
226
(2):
95-9
-
Getting at MYC through RAS.
Bachireddy P,
Bendapudi PK, Felsher DW.
Clin Cancer Res.
2005;
11
(12):
4278-81
-
Lethal cutaneous disease in transgenic mice conditionally expressing type I human T cell leukemia virus Tax.
Kwon H,
Ogle L, Benitez B, Bohuslav J, Montano M, Felsher DW, Greene WC.
J Biol Chem.
2005;
280
(42):
35713-22
-
Rehabilitation of cancer through oncogene inactivation.
Shachaf CM,
Felsher DW.
Trends Mol Med.
2005;
11
(7):
316-21
-
Suppression of p53 by Notch in lymphomagenesis: implications for initiation and regression.
Beverly LJ,
Felsher DW, Capobianco AJ.
Cancer Res.
2005;
65
(16):
7159-68
-
Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy.
Shachaf CM,
Felsher DW.
Cancer Res.
2005;
65
(11):
4471-4
-
Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer.
Giuriato S,
Rabin K, Fan AC, Shachaf CM, Felsher DW.
Semin Cancer Biol.
2004;
14
(1):
3-11
-
Oncogenes as therapeutic targets.
Felsher DW,
Semin Cancer Biol.
2004;
14
(1):
1
-
Putting oncogenes into a developmental context.
Felsher DW,
Cancer Biol Ther.
2004;
3
(10):
942-4
-
Reversibility of oncogene-induced cancer.
Felsher DW,
Curr Opin Genet Dev.
2004;
14
(1):
37-42
-
The E47 transcription factor negatively regulates CD5 expression during thymocyte development.
Yang Y,
Contag CH, Felsher D, Shachaf CM, Cao Y, Herzenberg LA, Herzenberg LA, Tung JW.
Proc Natl Acad Sci U S A.
2004;
101
(11):
3898-902
-
The human BCL6 transgene promotes the development of lymphomas in the mouse.
Baron BW,
Anastasi J, Montag A, Huo D, Baron RM, Karrison T, Thirman MJ, Subudhi SK, Chin RK, Felsher DW, Fu YX, McKeithan TW, Baron JM.
Proc Natl Acad Sci U S A.
2004;
101
(39):
14198-203
-
How cancers escape their oncogene habit.
Giuriato S,
Felsher DW.
Cell Cycle.
2003 Jul-Aug;
2
(4):
329-32
-
Pharmacological inactivation of MYC for the treatment of cancer.
Felsher DW,
Bradon N.
Drug News Perspect.
2003 Jul-Aug;
16
(6):
370-4
-
Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations.
Karlsson A,
Giuriato S, Tang F, Fung-Weier J, Levan G, Felsher DW.
Blood.
2003;
101
(7):
2797-803
-
c-Myc is a critical target for c/EBPalpha in granulopoiesis.
Johansen LM,
Iwama A, Lodie TA, Sasaki K, Felsher DW, Golub TR, Tenen DG.
Mol Cell Biol.
2001;
21
(11):
3789-806
-
Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts.
Felsher DW,
Zetterberg A, Zhu J, Tlsty T, Bishop JM.
Proc Natl Acad Sci U S A.
2000;
97
(19):
10544-8
-
Reversible tumorigenesis by MYC in hematopoietic lineages.
Felsher DW,
Bishop JM.
Mol Cell.
1999;
4
(2):
199-207
-
Transient excess of MYC activity can elicit genomic instability and tumorigenesis.
Felsher DW,
Bishop JM.
Proc Natl Acad Sci U S A.
1999;
96
(7):
3940-4
-
A novel octamer regulatory element in the VH11 leader exon of B-1 cells.
Goodglick L,
Felsher DW, Neshat MS, Braun J.
J Immunol.
1995;
154
(9):
4546-56
-
c-myc, MHCI, and NK resistance in immunodeficiency lymphomas.
Braun J,
Felsher DW, Goodglick LA.
Ann N Y Acad Sci.
1992:
651
467-9
-
Independent rearrangement of Ig lambda genes in tissue culture-derived murine B cell lines.
Felsher DW,
Ando DT, Braun J.
Int Immunol.
1991;
3
(7):
711-8
-
A murine model for B-cell lymphomagenesis in immunocompromised hosts: c-myc-rearranged B-cell lines with a premalignant phenotype.
Felsher DW,
Denis KA, Weiss D, Ando DT, Braun J.
Cancer Res.
1990;
50
(21):
7042-9
-
A murine model for B-cell lymphomagenesis in immunocompromised hosts: natural killer cells are an important component of host resistance to premalignant B-cell lines.
Felsher DW,
Rhim SH, Braun J.
Cancer Res.
1990;
50
(21):
7050-6
-
A rapid method for the purification of monomeric and/or dimeric phospholipases A2 in crotalid snake venoms.
Welches W,
Felsher D, Landshulz W, Maraganore JM.
Toxicon.
1985;
23
(5):
747-54
Navigation for This Section: Department of Medicine
Find a Researcher
Help